Key result
Calmodulin promotes adipose lipolysis and inflammation in cows with clinical ketosis via the TLR4/IKK/NF-κB pathway.
Why the study?
Clinical ketosis is accompanied by severe lipolysis and adipose tissue inflammation, with previous findings showing upregulated calmodulin (CaM), leading to the hypothesis that CaM regulates these responses.
Inhibiting calmodulin may act as an adaptive mechanism to alleviate metabolic dysregulation, lipolysis, and inflammation in the adipose tissue of cows with clinical ketosis.
Inhibiting calmodulin may alleviate adipose inflammation in ketotic cows; hypothesis-generating for metabolic pathways in other species.
Clinical ketosis is a crucial metabolic disease in dairy cows that is often accompanied by severe lipolysis and inflammation in adipose tissue. Our previous study suggested that the fold change of calmodulin (CaM) was upregulated 2.401-fold in the adipose tissue of cows with clinical ketosis. Therefore, we hypothesize that CaM may regulate lipolysis and inflammatory responses in clinical ketosis cows. To verify the hypothesis, we conducted a thorough veterinary assessment of clinical symptoms and serum β-hydroxybutyrate (BHB) concentration before collecting subcutaneous adipose tissue samples from six healthy and six clinically ketotic Holstein cows at 17 ± 4 days postpartum. Commercial kits were used to test the abundance of BHB, Non-esterified fatty acid (NEFA), Liver function index (LFI), interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α). We found that Clinical ketosis cows had higher levels of BHB, NEFA, LFI, IL-6, IL-1β, TNF-α, and lower glucose levels compared to healthy cows. Furthermore, the abundance of CaM, toll-like receptor 4 (TLR4), inhibitor of nuclear factor κB kinase subunit β (IKK), phosphorylated nuclear factor κB/nuclear factor κB, (p-NF-κB/NF-κB), adipose triglyceride lipase (ATGL) and phosphorylated hormone-sensitive lipase/hormone-sensitive lipase (p-HSL/HSL) were increased, while that of perilipin-1 (PLIN1) was decreased in the adipose tissue of cows with clinical ketosis. To investigate the mechanistic underlying the responses, we isolated the primary bovine adipocytes from the adipose tissue of healthy cows and induced the inflammatory response mediated by TLR4/IKK/NF-κB with lipopolysaccharide (LPS), in addition to treating with CaM overexpression adenovirus and CaM small interfering RNA. In vitro, LPS upregulated the abundance of CaM, TLR4, IKK, NF-κB, ATGL, p-HSL/HSL, and CaM and downregulated PLIN1. CaM silencing downregulated the abundance of LPS-activated p-HSL/HSL, TLR4, IKK, and NF-κB and upregulated PLIN1 in bovine adipocytes, except for ATGL. By contrast, CaM overexpression upregulated the abundance of LPS-activated p-HSL/HSL, TLR4, IKK, and NF-κB and downregulated PLIN1 expression in bovine adipocytes. In summary, these data suggest that CaM promotes lipolysis in adipocytes through HSL and PINL1 while activating the TLR4/IKK/NF-κB inflammatory pathway to promote an inflammatory response. There is a positive feedback loop between CaM, lipolysis, and inflammation. Overall, inhibiting CaM may act as an adaptive mechanism to alleviate metabolic dysregulation in adipose tissue, contributing to relief from lipolysis and inflammatory response.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2023) studied Clinical ketosis (n=12). Clinical ketosis and Calmodulin (CaM) modulation vs. Healthy cows and unmodulated controls was evaluated on Lipolysis and inflammatory markers (including BHB, NEFA, IL-6, IL-1β, TNF-α, TLR4, IKK, NF-κB). Calmodulin promotes lipolysis and inflammation in the adipose tissue of cows with clinical ketosis through the TLR4/IKK/NF-κB pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: